# A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

> **NCT04056117** · PHASE1,PHASE2 · COMPLETED · sponsor: **LimmaTech Biologics AG** · enrollment: 596 (actual)

## Conditions studied

- Shigellosis

## Interventions

- **BIOLOGICAL:** Shigella 4V
- **BIOLOGICAL:** MenACWY
- **BIOLOGICAL:** Rabies
- **BIOLOGICAL:** Diphtheria, Tetanus and Pertussis (DTaP)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04056117
- **Lead sponsor:** LimmaTech Biologics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-02
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-11-14
- **Target enrollment:** 596 (ACTUAL)
- **Last updated:** 2024-07-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056117, "A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04056117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*